OBIO | Orchestra BioMed Holdings, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	5.50 - 5.93
52 Week Range	4.22 - 11.69
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	34,697
Average Volume	126,416
Shares Outstanding	37,824,600
Market Cap	212,196,006
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-08-04

Valuation
Profitability
Growth
Health
P/E Ratio	-3.79
Forward P/E Ratio	N/A
EPS	-1.48
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	56
Country	USA
Website	OBIO

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

OBIO's peers: ATXS, EYPT, FENC, NVCT, OLMA, OMGA, IRON

*Chart delayed

Analyzing fundamentals for OBIO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see OBIO Fundamentals page.

Watching at OBIO technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on OBIO Technicals page.